» Articles » PMID: 32727387

Breast MRI Texture Analysis for Prediction of BRCA-associated Genetic Risk

Abstract

Background: BRCA1/2 deleterious variants account for most of the hereditary breast and ovarian cancer cases. Prediction models and guidelines for the assessment of genetic risk rely heavily on criteria with high variability such as family cancer history. Here we investigated the efficacy of MRI (magnetic resonance imaging) texture features as a predictor for BRCA mutation status.

Methods: A total of 41 female breast cancer individuals at high genetic risk, sixteen with a BRCA1/2 pathogenic variant and twenty five controls were included. From each MRI 4225 computer-extracted voxels were analyzed. Non-imaging features including clinical, family cancer history variables and triple negative receptor status (TNBC) were complementarily used. Lasso-principal component regression (L-PCR) analysis was implemented to compare the predictive performance, assessed as area under the curve (AUC), when imaging features were used, and lasso logistic regression or conventional logistic regression for the remaining analyses.

Results: Lasso-selected imaging principal components showed the highest predictive value (AUC 0.86), surpassing family cancer history. Clinical variables comprising age at disease onset and bilateral breast cancer yielded a relatively poor AUC (~ 0.56). Combination of imaging with the non-imaging variables led to an improvement of predictive performance in all analyses, with TNBC along with the imaging components yielding the highest AUC (0.94). Replacing family history variables with imaging components yielded an improvement of classification performance of ~ 4%, suggesting that imaging compensates the predictive information arising from family cancer structure.

Conclusions: The L-PCR model uncovered evidence for the utility of MRI texture features in distinguishing between BRCA1/2 positive and negative high-risk breast cancer individuals, which may suggest value to diagnostic routine. Integration of computer-extracted texture analysis from MRI modalities in prediction models and inclusion criteria might play a role in reducing false positives or missed cases especially when established risk variables such as family history are missing.

Citing Articles

Development and validation of ultrasound-based radiomics model to predict germline BRCA mutations in patients with breast cancer.

Deng T, Liang J, Yan C, Ni M, Xiang H, Li C Cancer Imaging. 2024; 24(1):31.

PMID: 38424620 PMC: 10905812. DOI: 10.1186/s40644-024-00676-w.


A nomogram model combining ultrasound-based radiomics features and clinicopathological factors to identify germline BRCA1/2 mutation in invasive breast cancer patients.

Guo R, Yu Y, Huang Y, Lin M, Liao Y, Hu Y Heliyon. 2024; 10(1):e23383.

PMID: 38169922 PMC: 10758804. DOI: 10.1016/j.heliyon.2023.e23383.


Predicting Breast Cancer Risk Using Radiomics Features of Mammography Images.

Suzuki Y, Hanaoka S, Tanabe M, Yoshikawa T, Seto Y J Pers Med. 2023; 13(11).

PMID: 38003843 PMC: 10672551. DOI: 10.3390/jpm13111528.


Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis.

Schulmeyer C, Fasching P, Haberle L, Meyer J, Schneider M, Wachter D Diagnostics (Basel). 2023; 13(3).

PMID: 36766486 PMC: 9914743. DOI: 10.3390/diagnostics13030372.


Comparing Characteristics of Pelvic High-grade Serous Carcinomas with and without Breast Cancer Gene Variants on MR Imaging.

Saida T, Shikama A, Mori K, Ishiguro T, Minaguchi T, Satoh T Magn Reson Med Sci. 2022; 23(1):18-26.

PMID: 36372398 PMC: 10838714. DOI: 10.2463/mrms.mp.2022-0061.


References
1.
Chang R, Chen H, Chang Y, Huang C, Chen J, Lo C . Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI. Magn Reson Imaging. 2016; 34(6):809-819. DOI: 10.1016/j.mri.2016.03.001. View

2.
Tomao F, Musacchio L, Di Mauro F, Boccia S, Di Donato V, Giancotti A . Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?. Gynecol Oncol. 2019; 154(1):138-143. DOI: 10.1016/j.ygyno.2019.04.009. View

3.
Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E . Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. JAMA Netw Open. 2019; 2(5):e194428. PMC: 6632150. DOI: 10.1001/jamanetworkopen.2019.4428. View

4.
Schrading S, Kuhl C . Mammographic, US, and MR imaging phenotypes of familial breast cancer. Radiology. 2007; 246(1):58-70. DOI: 10.1148/radiol.2461062173. View

5.
Zugazagoitia J, Perez-Segura P, Manzano A, Blanco I, Vega A, Custodio A . Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers. Breast Cancer Res Treat. 2014; 148(2):415-21. DOI: 10.1007/s10549-014-3167-4. View